ReviewImmunology2026
Vaginal Microbiota and Ovarian Cancer: A New Frontier in Immunomodulation and Diagnosis.
Review in Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Influence of Vaginal, Intestinal, and Tumor Tissue Microbiota on Selected Malignant Tumors in Women.International journal of molecular sciences · 2026Review
- Vaginal Microecological Imbalance, Human Papillomavirus Infection, and Cervical Carcinogenesis: Mechanisms and Clinical Implications.International journal of general medicine · 2026Review
- Epidural-Related Maternal Fever Is Associated With Structural Alterations in Vaginal Floral Homeostasis Among Parturients.Obstetrics and gynecology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian cancer remains one of the deadliest gynaecological cancers due to its often-late diagnosis and the absence of specific symptoms in the early stages. Beyond genetic alterations, the tumour microenvironment, including the vaginal microbiota, plays a decisive role in tumour progression. Recent studies have highlighted the involvement of microbial imbalance 'dysbiosis' in ovarian carcinogenesis, particularly through interactions with the immune system and the modulation of local inflammatory pathways such as Th17-related pathways. In a state of 'eubiosis,' the vaginal microbiota, dominated by Lactobacillus species, plays a protective role by producing lactic acid, maintaining an acidic pH, and preventing infections. Conversely, dysbiosis, characterised by a decrease in lactobacilli and an increase in opportunistic bacteria such as Gardnerella, Atopobium and Prevotella, promotes chronic inflammation through Toll-like receptor signalling, stimulates the production of IL-6, IL-8 and TNF-α, thereby creating a pro-tumour immune microenvironment conducive to tumour development. The complex interactions of the microbial flora, mucosal immunity, and tumour cells could explain the association between vaginal microbiota and ovarian cancer. This review highlights these mechanisms and emphasises the potential of vaginal microbiota as a tool for early detection and improved diagnosis of ovarian cancer. A better understanding of this microbe-host dialogue could pave the way for new prevention and detection strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.